trending Market Intelligence /marketintelligence/en/news-insights/trending/yex8py54T7HgB6O5TX824Q2 content esgSubNav
In This List

Cadila settles US FDA concerns at Indian facility

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Cadila settles US FDA concerns at Indian facility

Cadila Healthcare Ltd. settled concerns raised by the U.S. Food and Drug Administration following an inspection of the company's Baddi facility in India.

The company received a report from the FDA regarding the successful closure of inspection points, or 483s, raised by the regulatory body following the inspection of the facility between Feb. 21 and March 1, the company said in a news release.

The FDA previously issued three observation points regarding the facility, including concerns with the design of the facility's equipment, inadequate production and control records and incomplete information in batch production and control records.